😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Immunome completes $230 million stock offering

Published 2024-02-16, 04:34 p/m
© Reuters.

BOTHELL, Wash. - Immunome, Inc. (NASDAQ:IMNM), a biotechnology firm specializing in the development of cancer therapies, has completed a public offering of 10 million shares of common stock. This includes the full exercise of the underwriters' option to purchase an additional 1.5 million shares, bringing the total gross proceeds to $230 million, before underwriting discounts and commissions and offering expenses.

The shares were priced at $20.00 each, and the offering was conducted under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024, which became effective immediately. Both the preliminary and final prospectus supplements, along with the accompanying prospectus, are accessible on the SEC's website.

J.P. Morgan, TD (TSX:TD) Cowen, Leerink Partners, and Guggenheim Securities served as joint book-running managers for the offering, with Wedbush PacGrow acting as the lead manager.

The completion of this offering may bolster Immunome's financial position as it continues to develop its portfolio of cancer therapies. The company's approach includes a variety of drug modalities, such as antibody-drug conjugates (ADCs), radioligand therapies, immunotherapies, and small molecules, tailored to the biology of each target. Immunome's proprietary technology focuses on the rapid screening and functional characterization of novel antibodies and targets, which they believe could lead to transformative therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.